Trials / Completed
CompletedNCT00731237
XIENCE V® EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,517 (actual)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This trial is to assess physician-determined XIENCE V® EECSS acute performance, deliverability and resource utilization in the catheterization lab during commercial use by various physicians with a range of coronary stenting experience
Detailed description
This study will evaluate overall physician-determined XIENCE V® Everolimus Eluting Coronary Stent system (XIENCE V®) acute performance, deliverability and resource utilization in the catheterization lab in the "real world" as used by a broad group of physicians at a variety of health care facilities. This study will include all consecutively enrolled patients in the United States of America (USA) who consent to participate and receive XIENCE V® stents.
Conditions
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2009-03-01
- Completion
- 2009-10-01
- First posted
- 2008-08-08
- Last updated
- 2009-10-16
Locations
44 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00731237. Inclusion in this directory is not an endorsement.